STA No 204 Denosumab for the prevention of osteoporotic
fractures
This NICE guidance was published on 27 October
2010. The web reference for the appraisal and other related
documents is: http://www.nice.org.uk/TA204
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (651/10) on
this medication for this indication in December 2010. This stated
that:
Denosumab 60mg solution for injection in a
pre-filled syringe (Prolia®) is accepted for restricted
use in NHSScotland for the treatment of osteoporosis in
postmenopausal women at increased risk of fractures. It is
restricted to patients with a bone mineral density (BMD) T-score
< -2.5 and ≥ -4.0 for whom oral bisphosphonates are unsuitable
due to contraindication, intolerance or inability to comply with
the special administration instructions.
Access the advice of SMC:
3. There is a material difference between the
recommendations of the NICE STA and SMC. The NICE STA restriction
is based on age and number of independent clinical risk
factors as well as BMD, for primary prevention. For secondary
prevention there is no difference between the
recommendations.
Published Date: 27 October 2010
